Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.
A Thiery-Vuillemin1, A Llombart-Cussac, L Chaigneau
1Medical Oncology, University Hospital Jean Minjoz, Boulevard Flemming, Besancon, France. a.thieryvuillemin@mac.com
Breast (Edinburgh, Scotland)
|August 10, 2010
Summary
Starting neoadjuvant chemotherapy with taxane-based regimens in breast cancer patients did not impact efficacy but reduced anemia. The sequence order may be chosen based on toxicity profiles.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Standard neoadjuvant breast cancer treatment involves anthracycline followed by docetaxel chemotherapy.
- The study investigated the impact of reversing the sequence of anthracycline and taxane chemotherapy.
Purpose of the Study:
- To assess the impact of sequence order in neoadjuvant chemotherapy for breast cancer.
- To compare efficacy and toxicity between two different chemotherapy sequences.
Main Methods:
- A comparative study of 123 breast cancer patients treated between 2003 and 2007.
- Cohort T (65 patients): docetaxel followed by anthracycline. Cohort A (58 patients): anthracycline followed by docetaxel.
Main Results:
- Higher docetaxel dose intensity and clinical complete responses observed in Cohort T.
- No significant differences in conservative surgeries or histological responses.
- Anemia was significantly higher in Cohort A (81% vs 52%). Mild neurotoxicity was higher in Cohort T.
Conclusions:
- The sequence of taxane administration did not significantly impact overall treatment efficacy.
- Initiating neoadjuvant chemotherapy with taxane reduced the incidence of anemia.
- Sequence selection may be guided by patient-specific toxicity profiles.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...